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Background: Adverse effects of moderate Cannabis use on physical health are subtle and rarely fatal, 
while Cannabis use is associated with decreased rates of obesity, diabetes mellitus, mortality from 
traumatic brain injury, use of alcohol and prescription drugs, driving fatalities, and opioid overdose 
deaths. These data suggest that Cannabis use may decrease premature deaths. To date, no studies 
have attempted to estimate impacts of Cannabis use on premature death that include both adverse 
and beneficial effects on physical health.  
 
Methods: A systematic review, meta-analysis, and narrative summary of effects of Cannabis use on 
mortality are performed. Studies addressing the impact of Cannabis use on physiological systems and 
metabolism, and fatality rates following brain injury, are used with reported numbers of deaths from 
these causes and the proportion of the population using Cannabis to obtain an initial estimate of the 
effects of Cannabis use on premature death. Changes in death rates and alcohol consumption 
following legalization of medical marijuana are used with census data from states with legal access to 
estimate the impact of legalization of medical marijuana.  
 
Results: Marijuana use is estimated to reduce premature deaths from diabetes mellitus, cancer, and 
traumatic brain injury by 989 to 2,511 deaths for each 1% of the population using Cannabis. Using a 
monthly user rate of 12.2% in the analysis, this results in an estimated 12,100 to 30,600 deaths from 
these causes prevented annually due to marijuana consumption. Including MMJ, Cannabis use 
appears to prevent approximately 17,400 to 38,500 premature deaths annually under current policiesh. 
The analysis predicts an estimated 23,500 to 47,500 deaths prevented annually if medical marijuana 
were legal nationwide. A number of other potential causes of reduced mortality due to Cannabis use 
were revealed, but were excluded from the analysis because quantitative data were lacking. These 
estimates thus substantially underestimate the actual impact of Cannabis use on premature death. 
Including states with legal access as of 2015, prohibition is responsible for an estimated minimum of 
6,100 to 9,000 deaths annually due to lack of access to medical marijuana, in addition to the increased 
deaths from cancer, diabetes mellitus, and TBI arising from a decrease in the numbers of people using 
marijuana. Overall, prohibition is estimated to lead to similar numbers of premature deaths as drunk 
driving, homicide, or fatal opioid overdose. 
 
Conclusions: Cannabis use prevents thousands of premature deaths each year, and Cannabis 




There is growing acknowledgement of the medical and therapeutic benefits of the unique 
pharmacologically active compounds produced by Cannabis (marijuana). These compounds, known 
collectively as cannabinoids, include Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) that act 
on the endocannabinoid system of vertebrates and other animals [1]. Millions of people find relief from 
a variety of medical conditions including chronic and neuropathic pain, neurodegenerative and 
neuroinflammatory diseases, inflammation, and nausea and emesis using Cannabis [2-9]. In recent 
surveys of medical marijuana patients, eighty percent of patients report reduced use of prescription 
drugs upon initiation of medical marijuana, citing more effective relief of symptoms, less withdrawal, 
and fewer adverse side effects as reasons for the switch [10,11]. Prescriptions for drugs used to treat 
pain, anxiety, nausea, psychoses, seizures, sleep disorders, depression, and spasticity decrease 
following legalization of medical marijuana [12]. Decreases are also reported in use of illicit drugs and 
alcohol by medical marijuana (MMJ) patients [10,11,13].  
Recent reviews have addressed the adverse effects of Cannabis [14-17], and several have 
attempted to estimate the impact of Cannabis on the global burden of disease or the number of 
deaths caused by Cannabis use [18-21]. It is clear that heavy use of Cannabis has deleterious effects 
on health. However, these recent analyses only include deleterious effects of Cannabis use. Recent 
studies documenting potentially beneficial effects of Cannabis use on health are ignored. It is the net 
effect on health and mortality, including both adverse and beneficial effects, that is most important for 
public health - if only deleterious effects were considered, then water, food, and exercise would all be 
considered harmful. Furthermore, it should be obvious that non-fatal detrimental effects such as 
Cannabis use disorder are less important than effects on premature death. While use disorders can 
have significant negative impacts on quality of life, one can recover from use disorders. Premature 
death, on the other hand, is final. 
Evidence for harmful effects leading to a net increase in mortality due to Cannabis use is 
weak. A number of recent studies have found no increase in the mortality rate of Cannabis users. 
One study followed a cohort of users from age 18 to 38, and found that the only negative health 
outcome in the end of this period arising from Cannabis consumption was periodontal disease, while 
some health outcomes (HDL, cholesterol, triglyceride, and glycated Hb levels) were improved in users 
[22]. The failure to detect an association between Cannabis use and poor physical health in midlife 
was not due to better initial health, or healthier lifestyles in Cannabis users counteracting harmful 
effects of Cannabis use, but rather arose from an absence of any significant effect of Cannabis use 
(Meier et al. 2016) [22]. A study following adolescent users into their mid-thirties did not find any 
association of even heavy marijuana use with health problems [23]. Another longitudinal study found 
 
4  
no increase in mortality over fifteen years, after adjustment for social background variables, in a group 
of over 45,000 Swedish military conscripts [24]. Fuster et al. [25] found that daily Cannabis use was 
not associated with increased emergency hospital visits (aOR 0.67, 95% CI 0.36 – 1.24), or rates of 
healthcare utilization, among patients reporting use [25]. Sidney et al. found that, after accounting for 
increased rates of Cannabis use in AIDS patients, marijuana use was not associated with increased 
mortality [26].  One study from Switzerland even detected a dose dependent and significant decrease 
in the risk of injury with Cannabis use (OR = 0.33, 95% CI .12 - .92) [27]. There is thus little or no 
support for the hypothesis that moderate marijuana use leads to significant health problems, or 
increased mortality rates, even following years of use. 
While evidence is not consistent with moderate Cannabis use leading to fatal outcomes, even 
after years of use, there is emerging evidence suggesting that moderate Cannabis use may lead to 
significant positive health outcomes. A number of recent studies have shown lower rates of obesity, or 
healthier BMI, in current Cannabis users, effects that remain after full adjustment of the data for 
confounding factors [22,28-30]. The United States is in the midst of an obesity epidemic, and obesity 
is positively correlated with increased rates of a number of significant health issues, including cancer, 
cardiovascular disease, chronic kidney disease, diabetes mellitus, and Alzheimer’s disease [31,32]. 
These obesity-related diseases have a huge impact on public health. Given that extensive research 
has shown that deleterious effects on physical health are subtle, and generally are not fatal, this leads 
to the prediction that inclusion of beneficial effects in estimates of the public health impact of 
Cannabis use will reveal that Cannabis use decreases the premature death rate. The present 
systematic review and meta-analysis attempts to provide an initial, rough estimate of the overall 
effects of Cannabis use on the mortality rate that includes evidence for both beneficial and deleterious 
effects.  
 
Rationale: Recent studies have attempted to estimate the harm caused by Cannabis use from its 
effects on mortality and burden of disease. These studies are biased as they only consider 
deleterious effects and ignore substantial evidence for beneficial effects of moderate Cannabis use 
through effects on obesity rates and oxidative damage. The data available at this time thus suggest 
that the net impact of Cannabis use on public health, at least in terms of premature death, may be 
beneficial. Analyses considering both harmful and beneficial effects of Cannabis use in estimates of 






Objectives: The current study has four main objectives. These are:  
1. Identify in the literature quantitative data on causes of death influenced by Cannabis use. 
2. Determine whether available evidence on the impact of Cannabis use on physical health is 
consistent with a net beneficial or harmful impact on public health. 
3. Provide an initial, rough estimate the magnitude of the effects of Cannabis use on the rate of 
premature deaths in the U.S. 




Systematic review of the literature on the influence of Cannabis use on mortality: 
 
This research did not involve human subjects as it is a systematic review analyzing 
published data. The study was performed as a systematic review with meta-analysis and 
narrative synthesis following PRISMA protocols [33]. 
 
Review protocol: The effects of Cannabis use on mortality from effects on organ systems and disease 
states considered most likely to be influenced by Cannabis were investigated. These were cancer, 
appetite and metabolism, cardiovascular disease, liver disease, lung disease, and brain injury. Then, 
data on changes in mortality rates or harmful behaviors following legalization of medical marijuana 
were sought and analyzed.  The search engines Google Scholar and PubMed were used to identify 
relevant papers on these topics. The initial screen of the articles emerging from these searches 
selected papers reporting odds ratios or equivalent measures comparing rates of disease states in 
users and non-users, survival rates of users and non-users, or changes in fatalities following changes 
in legal status. Additional articles were sought in the reference sections of primary and review papers 
identified in this initial search. These studies were subjected to further analysis and supplemented 
with qualitative evidence allowing context. A second round of targeted searches was then performed 
for articles that illuminated issues arising in the initial search. The screen was performed twice, most 
recently in August 2016.  
 
Eligibility criteria: Studies published since 2000, that addressed the impact of marijuana on potentially 
fatal diseases, survival of accidents and accident rates, or the effects of legalization of medical 
marijuana on mortality, were sought. Relevant studies were in English. Studies included in the 
quantitative analysis must report quantitative data comparing the incidence of diseases, such as rates 
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of cancer, diabetes mellitus, cardiovascular disease, liver disease, or lung disease, in Cannabis users 
and non-users. To be included into the meta- analysis, studies must adjust for tobacco use and other 
confounding factors, and provide data for usage typical of the US population. 
 
Information sources: Google Scholar, PUBMED, and reference sections of identified research and 
review articles were screened for relevant papers. 
 
Search: The initial search for articles on the correlation between cancer rates and Cannabis use was 
performed using search terms “Cannabis and cancer” and ‘marijuana and cancer’. Search terms used 
for diabetes mellitus were “Cannabis and diabetes mellitus” and ‘marijuana and diabetes mellitus”. 
Search terms for traumatic brain injuries were “Cannabis and brain injury” and ‘marijuana and brain 
injury’. Search terms for cardiovascular disease were “Cannabis and cardiovascular disease” and 
“marijuana and cardiovascular disease”. Search terms for lung disease were “Cannabis and lung 
disease” and “marijuana and lung disease”. Search terms for liver disease were “Cannabis and liver 
disease” and “marijuana and liver disease”. For medical marijuana (MMJ), an initial search was 
performed using the phrases “Medical marijuana and mortality”, indicating possible effects on 
suicides, opioid use and overdose deaths, driving fatalities, and alcohol use. This initial search was 
followed by searches for “Cannabis and suicide” and “marijuana and suicide”, “Cannabis and opioid or 
opiate overdose” and “marijuana and opioid or opiate overdose”, “Cannabis and driving fatalities” and 
“marijuana and driving fatalities”, and “Cannabis and alcohol use” and “marijuana and alcohol use”, 
respectively. 
 
Data collection process: Citations appearing in database searches were copied into word and 
endnote files by search topic: i.e. Cannabis and cancer, Cannabis and DM, etc., and were initially 
screened for relevance by reading the title. Those articles selected in the initial screen were then 
considered in more detail by reading the abstract, and those providing data relevant to the study were 
then read in detail. Additional sources identified in reference sections of primary and secondary 
literature, and results of further searches to illuminate and clarify questions arising during the analysis 
of mortality data, were included in the analysis. 
 
Data items: Quantitative data for effects of Cannabis use on causes of death hypothesized to be 
influenced by Cannabis use were identified. Causes of death investigated included obesity-related 
diseases such as cancer, diabetes mellitus, cardiovascular disease, and Alzheimer’s disease, and 
diseases associated with exposure to toxins including liver disease and lung disease. Due to the well 
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known neuroprotective effects of cannabinoids, impact of Cannabis use on mortality from traumatic 
head injury was also investigated. The impact of legalization of medical marijuana on death rates was 
also investigated. 
Potential effects on other causes of death revealed during the search, but for which 
quantitative data are not available, were included in the qualitative analysis.  
 
Summary measures: The principal summary measure is changes in the rates of diagnoses and 
premature deaths due to Cannabis use, as estimated from published odds ratios or hazard ratios for 
disease states and TBI, and percentage changes in reported deaths following legalization of medical 
marijuana. 
 
Calculations to estimate the impact of Cannabis use on the mortality rate from impact on 
physical health: 
The search revealed data for cancer, diabetes mellitus, and traumatic brain injury that could be 
used to estimate the impact of Cannabis use on deaths. For cancer and diabetes mellitus, reported 
odds ratios, relative risk, or hazard ratios comparing users and non-users are used to estimate the 
effect of Cannabis use on the numbers of diagnoses and deaths from cancer and diabetes mellitus. 
While these are not identical measures, they are similar, represent the best data available, and can be 
used to provide a preliminary estimate of impact on premature death, revealing at minimum whether 
the impact is positive or negative and providing a rough estimate of the relative impact. For traumatic 
brain injury, the odds ratio for mortality of similarly injured patients testing positive and negative for 
Cannabis use are used. Estimates of the effects of Cannabis use on the number of fatalities from 
cancer, diabetes mellitus, and traumatic brain injury are calculated using Formula 1: 
 
Formula 1: E = DUR 
 
In formula 1, E = the change in diagnoses or deaths from a cause due to Cannabis use, D = reported 
annual number of diagnoses or deaths from that cause, R = (1 - the published odds ratio, hazard 
ratio, or relative risk), and U = the estimated Cannabis user rate as a percent of the population. 
Calculations are made the estimate of 12.2% the proportion of people age 12 and over using 
Cannabis in the previous month, from the National Health and Nutrition Examination Survey, 2007-
2010 [34], giving U = 0.122. A positive value for E is the estimated reduction in numbers of diagnoses 
or deaths from that cause due to use of Cannabis, whereas a negative value for E is the estimated 
increase in diagnoses or deaths as a result of Cannabis use. 
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Statistical methods for analysis of cancer data: 
 
When publications report relative rates of cancer for a variety of different usage patterns, the 
odds ratio for ever users versus never users (reflecting average or typical use), or for current users 
vs. non-users, from the fully adjusted model, was used as available. If these were not presented, the 
mean of the relative rates of cancer across user groups was used (see supplemental excel file). 
Numbers in 2013 of diagnoses for each cancer type were obtained from the American Cancer 
Society, and the numbers of deaths are the mean of numbers reported for 2013 by the American 
Cancer Society and the Centers for Disease Control, which differed slightly [35,36]. The number of 
deaths from HNSCC, pharyngeal cancer, or oral cancer were not reported in either the CDC or 
American Cancer Society databases [35,36]. Therefore, the estimate the impact of Cannabis use on 
cancers of the head and neck used the mean OR across undistributed HNSCC, nasal, oral, 
oropharyngeal, pharyngeal, and laryngeal cancers (mean = 0.83, 95% CI 0.64 – 1.02) with the sum of 
the numbers of diagnoses and deaths reported for these cancers (55,640 diagnoses and 13,005 
deaths) (Table 1, see also supplemental excel file). 
 
Screening of cancer studies: 
 
Studies that presented data on the impact of Cannabis use on cancer rates were selected and 
screened for data quality. Thirty one such articles were identified through database searches and 
through other sources (most of these were published prior to the cutoff date of 2000 used in the initial 
search) [37-68]. Only studies that provided odds ratios or hazard ratios that could be used to estimate 
the impact of Cannabis use on rates of cancer, that were adjusted for known confounding factors 
including tobacco or alcohol use, or demonstrated no effect of these factors on the cancer in question, 
were included in the analysis (Supplemental excel file). The studies meeting the selection criteria 
provided 38 data points (some studies provided odds ratios for multiple cancer types or sites) 
(Supplemental excel file). An additional 15 studies presented quantitative data but did not meet 
selection criteria and were removed during screening, as follows: the study by Zhang et al. [38] on 
lung cancer did not report data for ever vs. never users, or odds ratios that could be averaged across 
user groups. The study by Zhang et al. [39] reported an odds ratio of 2.6 for HNSCC, well outside the 
range of the data from other studies of head and neck cancers and HNSCC (mean = 0.83, 95% CI 
0.63 – 1.02, N = 17). This was found to be a statistical outlier using the Grubbs test [69] (P < 0.01, G 
= 2.91 > Gcrit = 2.821, N = 18, Ȳ = 0.93, and s = 0.57) and was eliminated from the analysis. Efird et 
al. [41] reported an odds ratio for Cannabis use and gliomas, but the study was designed to detect 
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effects of cigarette smoking, and included a large proportion of subjects who declined to state 
whether they used Cannabis. Furthermore, multiple laboratory studies have consistently shown that 
THC and cannabinoids eliminate gliomas in rats and destroy glioma cells in vitro with no cytotoxicity 
for surrounding cells [70,71]. A pilot clinical study in patients with recurrent, treatment resistant 
glioblastoma showed that THC decreased proliferation of the tumor cells [72], The reported odds ratio 
for gliomas [40] was therefore excluded from the analysis. Reports on effects of Cannabis 
consumption on cancer rates from studies performed in North Africa were excluded because 
Cannabis is consumed as hashish or kiff with tobacco in North Africa [41-46] and does not represent 
typical ingestion methods used in the US [47]. These studies consistently show higher rates of lung 
cancer than studies performed in the US or Europe. Other reports were excluded as follows. One 
study was rejected because no adjustment was made for tobacco and only the highest usage group 
was included (average 48 joint years) [45]. Five studies were rejected because no adjustment was 
made for tobacco use [46,48,51,63,65]. Three were rejected because the study did not report odds 
ratios nor present data that could be extrapolated to give an estimate of OR [49-51], and one was 
rejected because data for effects of Cannabis use were only reported for HIV positive patients who 
might be expected to have compromised immune systems [52]. 
 
Results:  
The systematic search results are presented as a PRISMA diagram (Figure 1). The primary database 
searches yielded 3605 articles. An additional 345 articles were identified through other sources. 
Removal of duplicates yielded a net of 1401 articles that were subjected to further screening. Of 
these, 898 were excluded and 503 were assessed further. A total of 222 articles were included in the 
qualitative analysis, and 23 were identified that provided data comparing relative rates of diseases of 
deaths in users and non-users, that could be used to estimate the impact of Cannabis use on the 
premature death rate. These were as follows: cancer (16), DM (2), TBI (1), driving fatalities (2), OD 






Figure 1: Prisma flow diagram of systematic search.  
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Effects on BMI and obesity. 
Emerging evidence demonstrates critical roles for the endocannabinoid system in appetite, 
food intake, energy balance, and metabolism [73]. The United States, and much of the developed 
world, is currently in the midst of an obesity crisis, and obesity is causally associated with a number of 
significant health problems including diabetes mellitus [31]. Diabetes mellitus (DM) is a leading cause 
of death worldwide, accounting for an estimated 3.96 million premature deaths (15.7% of all deaths), 
in the year 2010 [74]. The economic cost in 2007 of DM, in the US alone, was estimated at 174 billion 
dollars [75].  
Evidence strongly supports reduced obesity and diabetes mellitus in people who use 
Cannabis. The most common finding of studies to date have shown lower BMI, waist circumference, 
or rates of obesity in Cannabis users [22,28-30,76].  Le Strat and Le Foll [30] presented data from two 
epidemiological surveys, the National Epidemiologic Survey on Alcohol and Related Conditions 
(NESARC) and the National Comorbidity Survey – Replication survey (NCS-R). These data sets 
included 41,654 and 9,106 respondents, respectively. The prevalence of obesity was lower in 
marijuana users, and the proportion of obese individuals decreased with frequency of marijuana use, 
in both surveys. These effects remained after adjustment for confounding factors [30]. Rajavashisth et 
al. [76] reported that marijuana use was associated with a dosage-dependent decrease in the obesity 
rate, with the most frequent usage (≥ 5 times/month) showing one half the obesity rate of non-users, 
and the effects on obesity were dose-dependent and remained after adjustment for confounding 
factors. Ngueta et al. [29] investigated the relative rates of obesity among Inuits, and found a 
significant decrease in BMI in current Cannabis users (P < 0.001), who showed 56% the obesity rate 
of non-users. Meier et al. [22] showed decreased BMI in cannabis users. Because of these 
observations, Le Foll et al. [77] have proposed therapeutic use of Cannabis or THC for weight loss.  
 
Effects on Cancer. 
The relationship between Cannabis and cancer is complex. Cancer is positively correlated with 
obesity [31], and obesity decreases in a dose-dependent fashion with Cannabis use [28-30], whereas 
Cannabis smoke contains carcinogens. On the other hand, a casual examination of the literature 
reveals numerous laboratory studies demonstrating that cannabinoids have potent anti-tumoral 
properties in vitro and in mouse models. Cancers inhibited by cannabinoids include gliomas, thyroid 
epithelioma, lymphoma, neuroblastoma, and carcinomas of the oral region, lung, skin, uterus, breast, 
prostate, pancreas, and colon [70-72,79-87]. Thus, Cannabis may reduce the risk of getting cancer by 
reducing obesity rates and by direct inhibition of tumor formation or growth. In addition to these anti-
tumor and anti-obesity properties, there is growing interest in the use of Cannabis and cannabinoids 
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in palliative cancer care due to their abilities to reduce opioid use and counteract a number of 
negative effects of chemotherapy [88-90]. Potential palliative effects include suppression of nausea 
and emesis, bone loss, nephrotoxicity, and cardiotoxicity, as well as improving mood and outlook and 
providing relief from insomnia [88-90].  
Which effect predominates, the carcinogenic properties of the smoke, or the anti-tumor and 
anti-obesity properties of the cannabinoids? A recent review by Huang et al. [91] noted that some 
studies investigating the link between Cannabis use and cancer report decreased cancer rates in 
Cannabis users, while others report increased rates. Overall, however, they found no significant 
association between cancer rates and marijuana use. The current systematic review includes a 
number of data points not included in the study by Huang et al. [91], and screens the reports more 
aggressively. Furthermore, Huang et al. [91] made no attempt to relate the data for the effects of 
Cannabis use on risk of individual cancer types to the overall impact of Cannabis use on premature 
deaths from cancer. The current study attempts to do so using estimates of the proportion of the 
population using Cannabis, the odds ratios for cancer in users and non-users, and the number of 
deaths from cancer annually, for each cancer type. Thus, impacts of Cannabis use on cancers are 
weighted to take into account the numbers of diagnoses and deaths from each cancer type as well as 
the impact of Cannabis use, to determine the overall impacts on cancer deaths. 
The conclusions reached in the present study for cancers of the head and neck differ from 
those of the recent meta-analysis of de Carvalho et al. [92], who found no effect of Cannabis use on 
head and neck cancers (grand mean OR 1.02). The current analysis screened the data more 
carefully (see above). After screening of the data, the current analysis, using reported fully adjusted 
values from relative rates of cancer types comprising 1,159,120 (70% of total) cancer diagnoses and 
355,855 (61% of total) cancer deaths, yields a mean of 0.86, (95% CI = 0.77 - 0.96, N = 34) across all 
reported values meeting the selection criteria. The grand mean of values for each cancer site yielded 
a value of 0.89 (95% CI 0.75 – 0.98, N = 15). This estimate is lower than other studies due to a more 
complete search of the literature and more aggressive screening of the data, as described above. 
Many studies showed decreases in multiple user groups. The results of this analysis suggest that 
moderate Cannabis may reduce cancer rates in U.S. users. This effect would be expected to increase 
if consumers shifted to delivery methods other than smoking, such as edibles or vaping, thus avoiding 
the carcinogens produced during combustion. 
Meta-analysis: 
A total of 38 data points representing 15 cancer sites were found to meet the screening 
requirements and were accepted into the final analysis. Summary of these data points support 
decreased rates of cancer in Cannabis users. Of these 38 data points, 22 (58%) showed a relative 
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rate below 1.0, and only 12 (32%) showed a relative rate of cancer > 1.0 (Fig. 2).  
There is clear evidence justifying assumptions of causality for decreased cancer in users, in 
the abundant laboratory studies showing anti-tumor properties of cannabinoids [70-72,79-87] and in 
the dosage dependent decrease in BMI or obesity rates of Cannabis users [22,28-30,76]. The studies 
and data included in the cancer meta-analysis are presented in supplemental excel file and Table 1, 
and in Figure 2.  
When numbers of diagnoses and deaths from each cancer type with reported OR are entered 
into Formula 1 together with the reported OR for that cancer type, and using a user rate of 12.2% in 
the analysis, the analysis yields a decrease of 5,231 cancer diagnoses and 2,717 deaths each year 
(Table 1). These numbers for cancers with reported relative rates in users and non-users are used as 
lower estimates of the impact of Cannabis on cancer (Table 1). Odds ratios for Cannabis use on rates 
of a number of cancer types, including pancreatic, kidney, and uterine corpus cancers, are not 
available, but rates of these cancers are strongly correlated with obesity [93]. Pancreatic, kidney, and 
uterine cancers cause an additional 162,970 deaths/year (CDC) [35]. Because Cannabis users have 
significantly reduced rates of obesity relative to non-users [22,28-30,76], Cannabis is likely to reduce 
the risk of these cancer types even if it is found to have no direct anti-tumor activity on these cancers. 
This does not appear to be the case, however, as cannabinoids inhibit in vitro cell growth of uterine 
and pancreatic carcinomas, as well as thyroid epithelioma and neuroblastoma, other cancer types for 
which odds ratios are not reported [70-72,79-87]. The cannabinoids, with their potent anti-tumor 
properties, would be distributed throughout the body and thus expected to act on many distinct cancer 
types, whereas the carcinogens from Cannabis smoking would be at highest concentrations in certain 
organs (oral region, airways, lungs, esophagus) that have been the main targets of investigations of 
the effects of Cannabis on cancer rates. The overall effects of Cannabis use on cancer diagnoses and 
deaths is therefore likely to be greater than the effects estimated using data on cancers with reported 
OR. The overall effects of Cannabis use on all cancers were therefore extrapolated from cancers with 
reported OR using the mean reported relative incidences across cancer sites (mean OR = 0.89) and 
the total numbers of diagnoses and deaths from all cancer types (1,665,540 diagnoses and 585,720 
deaths, [35,36]). This extrapolation results in an estimated overall decrease of 22,351 diagnoses and 
7,860 deaths at an estimated user rate of 12.2%.  
Some of the cancer studies presented data that could be assigned to at least one of the 
following groups: low use (0-1 joint-year), medium use (1-10 joint-years), and high use (10+ joint-
years) (Supplemental excel files). In this subset of the data, the low and medium usage groups show 
significantly reduced rates of cancer relative to non-users (low usage: OR = 0.76, 95% CI 0.62 – 0.94; 
N = 22, medium usage: OR = 0.77, 95% CI = 0.63 – 0.92, N = 15). This decrease was not observed in 
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the high usage group (OR = 1.34, 95% CI = 0.83 – 1.85, N = 22) (supplemental excel file; Figure 3). 
The relationship between Cannabis and cancer therefore does not appear to be dose dependent. 















 H&N 55,640 13,005 0.83 (17) 1154 270 
Esophageal 17,990 14,950 0.61 (1) 856 711 
Lung 228,190 157,866 1.02 (5) -557 -385 
Prostate 238,590 28,701 1.3 (1) -8,732 -1,050 
Cervical 12,340 4,024 1.1 (1) -150 -49 
Colorectal 136,830 50,310 0.75 (2) 4,173 1,534 
Melanoma 76,100 9,710 1.15 (2) -1,393 -177 
Testicular 7,920 370 1.0 (5) 0 0 
Bladder 72,570 15,484 0.55 (1) 3,984 850 
Anal 7,060 880 0.8 (1) 172 21 
Penile 1,570 310 1.0 (1) 0 0 
Breast 234,580 40,678 0.8 (1) 5,724 993 
      
Lower Est. 1,159,120 355,855 0.86 (38) 5,231 2,717 
Upper Est. 1,665,540 585,720 0.89 (15) 22,352 7,860 
 
 
Table 1: Summary of effects of Cannabis use on cancer diagnoses and deaths, by cancer type. 
Effects of Cannabis use on mortality rates were calculated using Formula 1 with data in the Supplemental 
excel files, using an estimated user rate of 12.2%. The numbers of diagnoses and deaths reported for 
each cancer type in the year 2013 were obtained from the American Cancer Society and the Centers for 
Disease Control [35,36]. H&N refers to cancers of the head and neck include HNSCC, oral, 
oropharyngeal, pharyngeal, and laryngeal cancers. NHL refers to non-Hodgkin’s lymphoma. Positive 
values in the columns for reduction in diagnoses or deaths show a decrease, while negative values show 
increased diagnoses or deaths. “Lower Est.” shows the result across cancers with reported OR (70% of 
total cancer diagnoses and 61% of deaths) using the grand mean of the relative rates of cancer in users 
and non-users across studies, and is used as the lower estimate for effects of Cannabis use on cancer 
rates. “Upper Est.” is the estimate generated extrapolating the mean of reported relative incidence 
values by cancer site to all cancers, and is used as the upper estimate of effects of Cannabis use on 












































































































































Figure 2: Forest plot of adjusted cancer data. Data are represented as mean ± 95% CI of data reported in 
the Supplemental excel file. Relative frequency refers to raw data in the form of odds ratios, hazard ratios, 
and relative risk. HNSCC = head and neck squamous cell carcinoma, Pharyn = pharyngeal, larynx = 
laryngeal, esoph = esophageal, color = colorectal, melan = melanoma, TS = testicular seminoma, TNS = 
testicular nonseminoma, N-HL = non-Hodgkins lymphoma, m = men, w = women. Note that only one data set 
shows significantly higher rates of cancer in Cannabis users, and that nearly twice as many data sets show 
relative rates < 1 (N = 22) than > 1 (N = 12). The references and data used to create this figure are presented 
in the Supplemental excel file. 
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Figure 3: Effects of usage patterns on cancer risk. Some studies (identified in Table 1 with (UR) reported 
OR for low, medium, and heavy use. Values that could be categorized into low usage (0 – 1 joint-years; N = 
22), medium usage (1-10 joint years; N = 15), and high (10+ joint years; N = 22) usage rates were pooled. 
The references and data used to create this figure are presented in the Supplemental excel file. 





Effects on diabetes mellitus (DM) 
Diabetes mellitus (DM) is strongly correlated with BMI and obesity [31], and is also associated 
with inflammation [94]. Because Cannabis use reduces obesity rates, and cannabinoids have potent 
anti-inflammatory properties, Cannabis may decrease rates of DM. Two studies to date in the U.S. 
have compared rates of DM in Cannabis users and non-users, and both detected significantly 
decreased rates of DM in Cannabis users that hold up after adjustment for confounding variables 
[76,78]. Rajavashisth et al. [76] performed a multivariate model based on the Centers for Disease 
Control’s National Health and Nutrition Examination Survey (NHANES III), using data sets from 1988 
to 1994. This study included 10,896 adults, and robust multivariate analysis adjusting for 
sociodemographic variables, laboratory values, inflammatory marker, and comorbidity showed that 
Cannabis users had a large and significant reduction in rates of DM (fully adjusted OR 0.36, 95% CI 
0.24 – 0.55, P < 0.0001). This effect was driven primarily by differences in the 41- 59 year old age 
group. Users also showed reduced LDL and elevated HDL, and reduced serum glucose relative to 
non-users. Alshaarawy and Anthony [78] then replicated these results, analyzed yearly surveys from 
the NHANES and the National Surveys on Drug Use and Health over the years 2005 to 2012, yielding 
a meta-analytic summary-adjusted OR of 0.7 for DM (95% CI 0.6-0.8) [78]. This analysis also showed 
that past and present Cannabis users had lower serum insulin and measures of insulin resistance 
than non-users [78]. Ngueta et al. [29] and Penner et al. [95] did not compare relative rates of DM in 
users and non-users, but both reported reduced fasting insulin and insulin resistance among 
Cannabis users. HIV-HCV patients using Cannabis were found to have significantly lower rates of 
insulin resistance than non-users (OR 0.4) [96]. On the other hand, two smaller and more limited 
studies [97,98] failed to detect differences in plasma glucose levels between users and non-users.  
The study by Muniyappa et al. [97] consisted of only 30 users and 30 non-users, and the data were 
adjusted for BMI. The analysis by Rodondi et al. [98] was limited to young adults aged 18 – 30 years 
old, a group which did not show decreased rates of DM in the study by Rajavashiseth et al. (OR 0.93) 
[76]. 
The correlations between Cannabis use, DM, and improved blood lipid and glucose 
metabolism are supported by laboratory studies in mice. The incidence of DM in non-obese diabetes-
prone (NOD) mice was reduced from 86% to 30% with CBD treatment [99,100], and glucose uptake 
by insulin-resistant adipocytes is increased by exposure to THC in vitro [101]. There is thus strong 
evidence that Cannabis use significantly reduces the incidence of DM. Furthermore, cannabidiol is 
reported to be beneficial in diabetic cardiomyopathy [102], to reduce the endothelial inflammation and 
retinal damage caused by high blood glucose [103], and Cannabis sativa extracts protect against 
nerve damage in animal models of DM [104]. Thus, in addition to reducing the incidence of DM, 
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Cannabis appears to improve outcomes in people who develop DM, as well as improving quality of life 
by alleviating neuropathic pain [3,105]. 
 
Meta-analysis: 
Two large studies were identified that presented relative rates of DM in users and non-users, 
and both show significant decreases in DM in fully adjusted models [76,78]. There is clear evidence 
justifying the assumption of causality in the relationship between Cannabis use and DM, in the form of 
replicated observational studies showing dose-dependent effects of marijuana use on BMI and 
obesity, and improved blood glucose and lipid levels and decreased insulin resistance of users [22,28-
30,76,78,95,96]. Causation is further supported by studies of experimental models of the disease (i.e. 
NOD mice and adipocytes, [99-104]. The adjusted odds ratios provided by Rajavashisth et al. [76] and 
Alshaarawy and Anthony [78] were used in the analysis. In the US, there are approximately 1,700,000 
diagnoses of DM each year [106]. DM was reported as the cause of 75,578 deaths [35], and as a 
contributing factor in 234,051 deaths in the U.S. [106]. These numbers are similar to the estimate of 
Roglic et al. [74], of 313,208 deaths from DM in North America in 2010. Deaths from DM are almost 
certainly underreported [107]. For example, the cardiovascular damage caused by DM is a major 
cause of death from DM, yet only 39% of diabetes patients dying of cardiovascular disease had DM 
listed on the death certificate [108].  
In the current analysis, assuming that 12.2% of the adult population used Cannabis in the last 
month, Cannabis use is estimated to prevent 97,500 DM diagnoses annually. Upper and lower 
estimates of the impact on mortality suggest that Cannabis use prevents 4,300 to 17,800 premature 
deaths from DM annually (Table 2). The smaller value for each user rate is the estimate based on 
deaths for which DM was listed as the cause of death, and the larger value is based on total numbers 
of deaths with DM as cause or contributing factor. 
 
Effects on cardiovascular disease: 
 
Studies to date have failed to detect an effect of Cannabis use on atherosclerotic 
cardiovascular disease, or on cardiovascular health, or on net mortality from cardiovascular problems 
[28-30,109-111]. Cardiovascular disease is strongly associated with increased BMI and obesity, and 
both measures are reduced in Cannabis users [22,28-30,76]. Cannabis use is not correlated with 
cardiovascular risk factors, including hypertension, atherogenic dyslipidemia, or DM when alcohol 
and tobacco use are accounted for [76,95,96,111,112]. However, Cannabis smoking poses a risk for 
acute, potentially fatal cardiovascular episodes due to increased blood pressure and vasospasms 
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[113-124] . Many, but not all, of reported cases involve alcohol and/or other drugs [122], and deaths 
involving only Cannabis appear to be rare [114], although mortality is increased in patients who use 
Cannabis following MI [125,126]. However, tolerance to the acute cardiovascular effects develops 
rapidly [110,122], and over longer periods of use Cannabis reduces multiple risk factors for 
cardiovascular disease including DM and obesity [22,28-30, 76,68]. Furthermore, cannabinoid therapy 
reduces the progression of atherosclerosis in mice [127] and cannabinoids are potent inhibitors of 
inflammation [128], a hallmark of atherosclerosis thought to contribute strongly to its harmful effects 
[129]. Ingestion of cannabinoids (by means other than smoking) has been suggested as a way to 
reduce the progression of atherosclerosis [130]. CBD also protects the myocardium against ischemic 
reperfusion injury [131] and cannabidiol reduces the cardiovascular damage caused by elevated 
blood glucose levels characteristic of DM, a major cause of death associated with DM [102,103]. In 
addition, increased Cannabis use following legalization of medical marijuana is correlated with a 
decrease in alcohol consumption [13], and alcohol use is associated with an increased risk of stroke 
[132]. The neuroprotective effects of Cannabis are likely to reduce the risk of death and the extent of 
damage from strokes. Thus, the relationship between Cannabis use and cardiovascular disease or 
mortality is complex. Cannabis probably causes some deaths and prevents others. 
Jouanjus et al. [118] reported an average of 1.8 deaths/year from acute Cannabis-related 
cardiovascular accidents in France, a country with a regular user population of 1.2 million. Mittleman 
et al. [120] reported increased OR for CVA in the hour immediately following ingestion, and 
extrapolated an increased annual risk of a MI from 1.5 to 3% due to Cannabis use although they did 
not determine overall OR of users vs non-users. Rumalla et al. [112] detected an increased rate of 
acute ischemic stroke in Cannabis users, but the effect was modest (OR 1.17, 95% CI 1.15 – 1.20) a 
value lower than tobacco [112] and similar to the effect of ibupropen [133]. The magnitude of the 
response appears to be greatest in novice or occasional users and is rapidly attenuated with repeated 
use [110], so that longitudinal studies fail to detect increased rates of hospitalization in regular users 
[22-26]. Similarly, Barber et al. [115] and Westover et al. [134] reported overall OR for Cannabis use 
but both studies were rejected from the analysis, as follows. In the study by Barber et al. [115] only 
one patient did not also use tobacco, so no adjustment for tobacco use could be made, while 
Westover et al. [134] did not adjust for either alcohol or tobacco use. Evidence shows that Cannabis 
triggers acute CV accidents, this appears to be rare, similar to the risk posed by ibupropen and lower 
than tobacco, the risk appears to be rapidly attenuated in regular users, and regular use reduces 






The available data shows no net effects of Cannabis use on mortality rates from 
cardiovascular disease, stroke, or MI, as multiple studies have failed to detect such effects [22-
24,109-112,130,135]. Cannabis lowers risk of cardiovascular disease but also triggers acute 
cardiovascular accidents, effects that may counteract each other. A net effect of zero is used in the 
summary (Table 2). More research is needed in this area to identify delivery methods with lower risk, 
and people with cardiovascular disease who are considering initiation of medical use of Cannabis 
should be warned of the potential risk.  
 
Effects on lung disease: 
 
Numerous studies address effects of Cannabis use on lung and respiratory system health. 
While many articles report respiratory problems arising from Cannabis smoking, especially at high 
usage rates, it is clearly less harmful than tobacco [137]. No consistent association has been found 
between Cannabis use and lung cancer after accounting for confounding factors [138,139]. This result 
was supported by the current study, in which the mean adjusted odds ratio for lung cancer across 
those studies that met acceptance criteria was 1.03 (N = 4; supplemental excel file). On the other 
hand, reports of acute injury to lungs during Cannabis smoking are not uncommon, and heavy, 
chronic Cannabis use is clearly associated with increased airway resistance, symptoms of bronchitis, 
lung hyperinflation, and inflammation of the lungs as well as cellular changes resembling those 
caused by tobacco smoking prior to onset of cancer [140,141]. Case studies suggest that heavy 
Cannabis use may be associated with bulla formation or histopathological changes predisposing to 
emphysema, lung cancer, or pneumothorax [142-144] although a systematic review concluded that a 
causative link with bullae is unlikely [145] or represent uncommon responses in exceptionally heavy 
smokers [146]. A recent longitudinal study did not detect significant lung problems following 20 years 
of use [22]. There is also no clear link of Cannabis smoking with lung fibrosis as Cannabis use is 
associated with increased measures of lung volumes or capacities, including total lung capacity, 
forced vital capacity, functional residual capacity, or residual volume [22,34,139,140,146]. The data 
are inconclusive for increased rates of lower respiratory tract infections arising from the chronic 
bronchitis from frequent use [139]. Contaminants of Cannabis such as Aspergillis have been reported 
to cause serious lung problems in medical marijuana patients, especially those who are 
immunocompromised [147,148]. Patients should be made aware that the harms to the lungs and 





While frequent or heavy Cannabis smoking is associated with respiratory tract problems, and it 
may exacerbate the respiratory problems arising from tobacco use [150], Cannabis use by itself does 
not appear to increase mortality from respiratory problems, and no quantitative data on disease 
incidence or mortality are available for estimates of mortality from such problems. A net effect of zero 
is included in the meta-analysis of effects of Cannabis use on premature death from lung disease 
(Table 2). 
 
Effects on liver disease: 
There are at this time no data showing changes in mortality from liver disease arising from 
Cannabis use. Cannabinoids both stimulate and inhibit liver fibrosis, depending on the receptor 
activated, and cannabinoids enhance liver steatosis [151-153] and may exacerbate effects of hepatitis 
C on the liver [154,155]. A cross-sectional study reported a strong correlation between daily marijuana 
use and moderate to severe liver fibrosis in individuals infected with HCV [155]. In another study, daily 
marijuana use was correlated with increased steatosis in patients with chronic hepatitis C [156]. 
However, a subsequent longitudinal study did not support causation of liver disease by Cannabis in 
such patients [157], finding no evidence that Cannabis use accelerated fibrosis (Hazard Ratio 1.02 (CI 
0.93 – 1.12) or cirrhosis (HR 0.99 (0.88 – 1.12) [157]. Instead, the evidence was consistent with the 
correlation having arisen due to self-medication to treat the symptoms of liver disease [157]. Thus, 
Cannabis does not appear to increase mortality from liver disease in the absence of underlying 
disease states such as hepatitis C or toxin exposure, but may interact with other factors that cause 
harm to the liver.  
On the other hand, legalization of medical marijuana results in a reduction in alcohol 
consumption [13], and reduces the use of prescription pain and other medications [12], actions that 
would reduce injury to the liver. For example, the popular over-the-counter pain medication 
acetaminophen was involved in 881 overdose deaths in 2010 [158] and is a common cause of liver 
toxicity. Combining acetaminophen and alcohol is especially harmful. Furthermore, nonalcoholic 
steatohepatitis is significantly correlated with obesity and insulin resistance, leads to cirrhosis, and is 
the third- most important indication for liver transplant [159,160]. The decrease in BMI and insulin 
resistance in Cannabis users [22,28-30,76,78,95,96] could therefore reduce nonalcoholic 
steatohepatitis in Cannabis users. 
No published OR values for nonalcoholic steatohepatitis in Cannabis users, or data addressing 
whether mortality from liver disease is influenced by Cannabis use, were encountered during the 
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search, but it is possible that Cannabis use could reduce deaths from liver disease due to these 
indirect effects.  Patients should be urged to use strains high in CBD, or avoid high THC-low CBD 
strains, due to potential aggravation of harmful effects of other drugs and alcohol by activation of liver 
CB1 receptors.  
 
Meta-analysis: 
Both beneficial and harmful effects of Cannabis use are detected, but no quantitative data 
showing relative rates of liver disease in users and non-users were identified that could be used in the 
analysis. The effect of Cannabis use on premature death from liver disease was detected in the study, 
and a value of zero is included in the meta-analysis (Table 2). Further research is strongly merited 
especially for potential beneficial effects and for further evaluation of the potential for harmful 
interactions with other drugs.  
 
Effects on deaths from traumatic brain injury (TBI): 
 
Cannabinoids have well known neuroprotective effects, reducing damage from excitotoxicity, 
Ca++  influx, free radical formation, and neuroinflammation following traumatic brain injury (TBI), 
ischemia, and neurotoxins [161-167,169-171]. Two studies were identified that addressed relative 
mortality rates of Cannabis users and non-users from traumatic brain injury [167,168]. Both these 
studies reported reduced mortality in Cannabis users, but only one [167] presented quantitative data 
on relative survival rates of Cannabis users and non-users. The study by O’Phelan et al. [168] 
reported an odds ratio of 0.33 for all illicit drug use but did not report data for Cannabis specifically, 
and was therefore excluded from the analysis. The remaining study [167] reported an odds ratio for 
mortality, following comparable TBI, of 0.224 (P < 0.05). This neuroprotective effect of Cannabis use in 
survival of brain injuries is supported by several clinical and laboratory studies.  Knoller et al. [169] 
reported that patients with severe closed head injuries who were administered the synthetic 
cannabinoid HU-211 showed highly significant decreases in the duration of elevated intracranial 
pressures, reduced cerebral perfusion pressures, and decreased systolic blood pressures, and 
showed better outcomes at three and six months, relative to patients who did not receive the drug. 
Similarly, application of CBD to rats resulted in long-lasting neuroprotection from hypoxia and 
ischemia [170], and the endogenous cannabinoid 2-AG is neuroprotective following brain injury [171]. 
Of course, increased rates of TBI in Cannabis users would offset increased survival following 
injury. The evidence at this time does not support significant increases in rates of head injuries due to 
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Cannabis use, however. Effects of Cannabis use on coordination are quite different from alcohol. 
Even at high doses, Cannabis has no noticeable effect on the ability of experienced users to ride a 
bicycle [172]. Several studies [22-27,173-174] were identified that addressed the relative rates of 
injury, hospitalizations, or TBI in Cannabis users. Bechtold et al. [23] found no difference in 
incidences of concussions among Cannabis user groups. Kolakowsky-Hayner et al. [173] found no 
statistical differences in Cannabis use prior to brain and spinal cord injury, and Tait et al. [174] found 
that marijuana problems did not predict subsequent serious brain injury. Meier et al. [22] found no 
associations between persistent cannabis use and health outcomes in early midlife after years of 
use, and noted that the lack of effects was not driven by better health when Cannabis use was 
initiated [22]. Fuster et al. [25] identified no correlation between rates of emergency room admissions 
and frequency of Cannabis use. Gmel et al. [27] reported a dose-dependent reduction in risk of injury 
in Cannabis users (RR: 0.33; 95% CI = 0.12 - 0.92), though the sample size for Cannabis users was 
small. Two studies finding increased rates of hospitalizations were rejected. Ilie et al. [175] failed to 
account for alcohol use. Gerberich et al. [176] identified increased rates of injury hospitalizations in 
past and present Cannabis users, driven by increased motor vehicle accidents, assaults (men) and 
self- inflicted injuries. However, a recent major study found that the correlation of Cannabis use with 
motor vehicle accidents disappeared when the data were adjusted for confounding factors [177]. 
Assaults correlated with Cannabis appear to be linked to prohibition rather than Cannabis use itself 
as assaults and homicides have decreased in Colorado following legalization of Cannabis [178]. Self-
injury would appear to be related to underlying mental health issues correlated with Cannabis use, 
and not Cannabis use itself [179]. Effects of Cannabis consumption on driving accidents are 
discussed below, and also do not support increased rates of head injury from automobile accidents 
due to Cannabis use.  
Any increase in accident rates would need to be substantial to offset the reported increase in 
survival following injury (OR for death = 0.224) [167], and effects of this magnitude would be readily 
apparent. Available evidence thus suggests that the increased survival of Cannabis users following 
brain injury is not offset by increased injury rates arising from Cannabis use. 
 
Meta-analysis: 
Nguyen et al. [167] presented the only data that could be used to estimate effects on 
premature deaths. Justification of assumptions of causality arise from studies demonstrating 
neuroprotective effects of cannabinoids [161-166,169-171]. The CDC reports 53,014 traumatic brain 
injury deaths in 2013 [35]. Using these numbers, an estimated additional 3,003 to 5,019 deaths 
(estimated with a 12.2% user rate) would have occurred from TBI had no Cannabis consumption 
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taken place in 2013. These numbers are reported in the meta-analysis (Table 4). It is not clear what 
fraction of the reported percentage of the population using Cannabis each month would test positive 
at the time of injury, so this analysis may overestimate the impact of Cannabis use on deaths from 
TBI by assuming all Cannabis users who were in accidents tested positive at the time of the accident. 
However, cannabinoids linger in the body for a significant period of time following ingestion [180], and 
many of the patients who tested positive may not have been impaired at the time of the accident. 
 
Effects on neurodegenerative and neuroinflammatory diseases and epilepsy: 
 
Cannabinoids reduce the symptoms and progression of a number of neurodegenerative and 
neuroinflammatory diseases, including Alzheimer’s disease, multiple sclerosis, amylotropic lateral 
sclerosis, Parkinson’s disease, and Huntington’s chorea [2,4-8,181-186]. They are also protective 
against toxins [164-166]. The data on Alzheimer’s disease are particularly interesting. This disease is 
associated with neuroinflammation, excitotoxicity, oxidative stress, and reduced mitochondrial activity 
in the brain, and is characterized by the formation of aggregations of amyloid β peptide and 
neurofibrillary tangles [5]. Inflammation associated with microglia plays a key role in progression of 
Alzheimer’s [184], and microglia-associated inflammation at senile plaques is strongly suppressed by 
low doses of THC [182]. Molecules of particular interest in Alzheimer’s pathology, and thus in 
development of treatment options or preventative therapies, include acetylcholinesterase, glycogen 
synthase-3 (GSK-3β), phosphorylated tau, and amyloid β. Laboratory studies suggest that 
cannabinoids slow or stop the progression of Alzheimer’s through actions on each of these targets. 
Low doses of THC inhibit the actions of acetylcholinesterase on amyloid β-peptide aggregation [181], 
and reduce levels of GSK-3β, phosphorylated GSK-3β, and phosphorylated tau protein, while 
simultaneously increasing mitochondrial activity [5]. Recently, Currais et al. [186] showed that THC 
caused dissociation of existing amyloid β plaques, characteristic of not only Alzheimer’s disease but 
also associated with the general mental declines characteristic of the aging brain. These data are 
supported by Marchalant et al. [187], who showed that cannabinoids attenuate the 
neuroinflammation and decline in neurogenesis associated with aging in the mouse brain. Another 
recent study showed rejuvenation of the aging mouse brain through changes in gene expression, 
resulting in improvements in learning and memory, in response to low doses of THC [188]. Thus, 
laboratory studies show that THC and other cannabinoid receptor agonists act via multiple pathways 
to reduce Alzheimer’s pathology and improve function of the aging brain [2,5,6,128,181-188]. 
Other brain diseases also benefit from the neuroprotective and anti-inflammatory properties 
of cannabinoids. Parkinson’s disease is caused by loss of dopaminergic neurons in the substantia 
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nigra. Cannabis ameliorates the bradykinesia, rigidity, and tremor that are symptoms of Parkinson’s 
disease, and reduces progression of the disease [4,7]. Multiple sclerosis, ALS, and Huntington’s 
disease also benefit from cannabinoids [2,4,6,183]. Cannabis and cannabinoids reduce or, in a few 
patients, eliminate the frequent seizures of patients with treatment-resistant epilepsy [189]. Families 
of some such patients have become medical refugees, moving from states with more repressive 
policies to Colorado for legal access to potentially life-saving cannabinoids. Alzheimer’s is reported 
as the cause of 84,747 deaths annually [35], although a recent study suggests that deaths from 
Alzheimer’s may be as high as 503,000 annually [190]. Parkinson’s disease is responsible for 25,196 
deaths annually [35], while epilepsy causes approximately a three-fold increase in mortality [191] 




There is clear theoretical evidence that Cannabis should reduce mortality from 
neurodegenerative and neuroinflammatory diseases, and may actually reduce the incidence or slow 
the onset of Alzheimer’s and other diseases. However, no quantitative data showing relative rates of 
these diseases, or survival from these diseases, were identified in the analysis. Emerging evidence 
also shows significant neuroprotection against toxins and improved function of the aging brain. 
However, no data are available at this time showing relative incidences or mortality rates of 
Alzheimer’s or other neurodegenerative diseases in Cannabis users and non-users. These diseases 
therefore could not be included in the estimates. However, a hypothetical 5% decrease in mortality 
from Alzheimer’s disease due to Cannabis use, assuming that the age group prone to Alzheimer’s 
disease uses Cannabis at a 3% user rate (lower than the national average among adults), results in 
prevention of an estimated 127 to 745 deaths each year. If this population used Cannabis at rates 
similar to the general population (12.2%), and upper estimates of deaths from Alzheimer’s disease 
[190] are used in the analysis, Cannabis use would prevent or delay approximately 3,100 deaths 
annually due to Alzheimer’s disease. In addition, Jones et al. [158] showed that antiepileptic and 
antiparkinsonism drugs contributed to 1,717 overdose deaths in 2010. Presumably, as with opioids, 
reducing use of these drugs through increased availability and use of Cannabis would reduce these 
overdose deaths as well. However, as we do not have odds ratios for incidence of or deaths from 
neurodegenerative diseases in Cannabis users, or for effects of medical marijuana on use of these 





Disorder Percent of population using Cannabis 
 12.2% Each 1% of adult 
population using 
Cannabis Cancer diagnoses 5,231 – 22,352 429 - 1,832 
Cancer deaths 2,717 – 7,860 223 - 644 
DM diagnoses 97,478 7,990 
DM deaths 4,334 – 17,754 355 – 1,455 
CV disease No net impact detected No net impact detected 
Lung disease No net impact detected No net impact detected 
Liver disease No net impact detected No net impact detected 
Traumatic Brain Injury 5,019 411 
Neurodegenerative 



















Table 2: Summary of the separate meta-analyses showing estimated decreases in diagnoses and 
premature deaths of Cannabis use due to health impacts. Estimates of effects of Cannabis use on 
diagnoses and premature deaths, at the reported population user rates of 12.2%, and for each 1% change in the 
proportion of the population using Cannabis, are reported for physical health parameters hypothesized to be 
influenced by Cannabis use. Odds ratios were only available for cancer, DM, and TBI, and these all showed a 
decrease in death rates with Cannabis use. Available data do not support net increases in mortality from 
cardiovascular disease, liver disease, or lung disease due to Cannabis use, while evidence supports prevention 
of deaths from neurodegenerative diseases and epilepsy but quantitative data are lacking. 
 
Changes in the mortality rate following legalization of medical marijuana. 
 
In order to more completely estimate the impact of Cannabis use on premature deaths, the 
effects of legalization of medical marijuana were also investigated. Driving fatalities, opioid overdose 
deaths, and alcohol consumption have all been found to decrease following legalization of medical 
marijuana. The apparent impact of medical marijuana on the mortality rate from these causes is 
estimated below. 
 
Calculations to estimate the impact of legalization of medical marijuana on the mortality rate:  
 
Legalization of MMJ has been reported to influence suicides, opioid overdose deaths, driving 
fatalities, and alcohol use. The impact of Cannabis use on each of these causes of death was 
explored further using Google scholar and PubMed as described above. The number of fatalities 
from these causes prevented or caused by medical Cannabis use (MMJ) in the United States each 




 Formula 2: E = D(%change/100) 
 
The change in numbers of deaths from each cause, per state, is estimated by assuming a 
random distribution of deaths across all states based on their population. Data on the total numbers 
of fatalities/year from each cause [35] are multiplied by the fraction of the U.S. population living in 
each state with legal access to MMJ (as of 2015; obtained from the U.S. census) to arrive at a rough 
estimate of the number of fatalities occurring per year from that cause in that state (Table 3). Formula 
2 is then used with these data to estimate the impact of Cannabis use on fatalities from each cause of 
death per year in each state. This is by necessity an initial rough estimate ignoring heterogeneity 
among states. The results were then summed across states to determine the impact of legalization of 
medical marijuana nationwide. To estimate the deaths prevented if MMJ was legal nationwide, 
formula 2 was applied to the total annual number of deaths from each cause nationwide.  
Effects of medical marijuana on fatal opioid overdoses: 
 
Opiate prescription painkillers are widely used, high risk drugs with strong potential for abuse, 
addiction and fatal overdose. Opioid overdose deaths are spiking, and medical Cannabis use has 
been shown to reduce opioid dose and usage by as much as 64% in the treatment of chronic pain, 
reducing side effects and improving quality of life [194-197]. Data such as these lead to the 
proposition that medical Cannabis use is a safer option to reduce the harm and morbidity from opioid 
use for treatment of pain [196]. This proposal is supported by the demonstration that legalization of 
medical marijuana leads to significant drops in hospitalizations from opioid pain reliever, without 
impacting hospitalizations related to marijuana [197]. States legalizing MMJ have seen a reduction of 
24.8% in the rate of fatal opioid overdose deaths in the first 5 years following legalization, and a 33% 
decrease after 5 years, relative to states without such legal access [192]. About 60% of the fatalities 
had resulted from a prescription obtained from a single provider, suggesting that many of these deaths 
were accidental overdoses during treatment of pain [192]. This decrease in OD deaths held up when 
suicides were eliminated from the data set, and appears to arise from substitution of Cannabis for 
opioids [10-12,194-199]. It should be noted that many overdose deaths involve prescription drugs 
other than opioids [158]. For example, in 2010 there were 3,889 reported overdose deaths from 
antidepressants, 2,239 in combination with opioids, 1,717 from antiepileptic and antiparkinsonism 
drugs, 1,125 in combination with opioids, 6,497 overdose deaths from benzodiazepines (used to treat 
anxiety, insomnia, and as a muscle relaxant), 5,017 in combination with opioids), 881 overdose deaths 
from acetaminophen, and 228 from NSAIDS [158]. Most medical marijuana patients (80%+) report 






           





























Table 3: State legalization and census data used to estimate effects of medical marijuana on 
death rates. States legalizing medical marijuana as of 2015 are included in the analysis. For each 
state that has legalized medical marijuana, the state population as a percentage of the total US 
population is shown. Data on total U.S. and state populations were obtained from the U.S. census. 
These data are used to estimate changes in death rates from reported changes in opiate OD, driving 









Cause of death Fatalities
/ year 
Annual deaths 
prevented in states 
with legal MMJ 
Annual deaths prevented 
if MMJ was legal 
nationwide 
Opiate OD 16,235 2,227 4,759 
Alcohol, excl. 
driving 
77,924 1,823 to 3,865 3,859 to 8,258 
Driving 
fatalities 
35,369 1,324 to 1,820 2,829 to 3,890 
Total  129,528 5,400 to 7,900 11,500 to 16,900 
 
Table 4: Summary of meta-analysis of estimated reductions in premature deaths following 
legalization of medical Cannabis. 
 
Opioid overdose fatalities: Estimates are based on 16,235 prescription opioid overdose fatalities 
nationwide/year for 2013 [35]. For years 1-5 following legalization, a reduction of 24.8 % was used in 
calculations, whereas for years 6- present post-legalization the reduction of 33% was used, as reported by 
Bachhuber et al. [192]. 
Driving fatalities: Estimates of changes in driving fatalities are based on 35,369 driving fatalities/year 
nationwide [35]. Data on the reduction in driving fatalities was estimated using the 8 to 11% decrease following 
legalization, as reported by Anderson et al. [13]. 
Other alcohol-related deaths: Alcohol-related deaths from causes other than driving fatalities were estimated 
using 88,000 alcohol related deaths/year (National Institute on Alcohol Abuse and Alcoholism [193]), from which 
the estimated numbers of drunk driving fatalities/year were subtracted, giving an 77,924 alcohol-related non-
driving deaths nationwide. A lower estimate for the decrease in alcohol related deaths other than driving was 
established using the 5% decrease in overall alcohol consumption, and an upper estimate using the 10.6% 
decrease in numbers of drinks consumed, as reported by Anderson et al. [13]. These data were used in 




Assumptions of causality are clearly justified by the substitution of Cannabis for pharmaceutical 
pain relievers [10-12,194-199]. Bachhuber et al. [192] presented the only data that could be used to 
estimate impacts on mortality rates. Using the 24.8% reduction in the first 5 years and 33% reduction 
thereafter, this rate of reduction in overdose deaths translates to an estimated 2,227 fewer overdose 
deaths/year in 2015 in states with legal medical marijuana. If MMJ were legal nationwide, this number 
would increase to 4,800. This number does not account for people who illicitly reduced opioid use with 
Cannabis prior to legalization or do so at present in non-MMJ states. 
Recently, Bradford and Bradford [13] showed that legalization of medical marijuana was 
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associated with decreases in prescriptions for drugs to treat pain, nausea, psychosis, seizures, sleep 
disorders, depression, and spasticity, suggesting that overdose deaths from non-opioids used to treat 
these conditions should decrease as well. In addition, medical Cannabis use is associated with 
reduced use of alcohol [10,11,13] and mixing alcohol with prescription drugs greatly increases the 
risk of harm. Thus, it is likely that substitution of Cannabis for these other pharmaceuticals, and for 
alcohol, would further reduce overdose deaths. An analysis to test this hypothesis has not been 
performed to date and no data are available for inclusion in the meta-analysis. 
 
Effects of medical marijuana on alcohol consumption: 
 
Alcohol is a high risk drug [200,201]. The National Institute on Alcohol Abuse and Alcoholism 
reports approximately 88,000 alcohol-related deaths/year in the US [193]. The relative risks posed by 
drugs can be quantified using the margin of exposure (MOE), defined as the ratio between the 
toxicological threshold and the estimated human intake. Low MOE numbers indicate high risk. For 
individual users, the MOE for alcohol is less than 10, signifying high risk, whereas the MOE of THC is 
> 100, the lowest risk category. For the overall population, alcohol also ranks as a much higher risk, 
with MOE < 10 compared to Cannabis with MOE > 10,000 [200,201]. Thus, according to any objective 
analysis alcohol is far more dangerous than Cannabis. Alcohol causes mortality in several ways, 
including acute overdose, increased risk of driving fatalities and other fatal accidents, and chronic liver 
disease, and alcohol use is strongly correlated with violent crimes including assault, domestic 
violence, and homicide [202]. Alcohol ranked as the fifth leading risk factor for disease in 2010, with 
an average of 25,793 deaths/year in the US from direct health effects of alcohol [202]. Replacement of 
alcohol with Cannabis should therefore reduce the death rate. 
The relationship between Cannabis use and alcohol consumption is complex [203].  
Cannabis has been found to substitute for alcohol in MMJ patients [10,11,13,198-199], and 
alcohol and tobacco use by teens increases during periods of Cannabis abstinence and decreases 
again upon resumption of Cannabis use, though these effects were not observed in individuals who 
remained abstinent after one month [204]. In contrast, decriminalization appears to have little 
consistent impact on alcohol use [reviewed by 203], while Cannabis use predicted increased 
incidence of alcohol use disorder in a longitudinal study [205].  
Effects of MMJ legalization on driving fatalities and other alcohol-related deaths are analyzed 
separately below, because we have data specifically addressing effects of legalization of medical, but 




Effects of medical marijuana on driving fatalities: 
 
Effects of Cannabis intoxication on driving: The effects of Cannabis on driving are clearly distinct from, 
and less detrimental than, alcohol [206]. Effects of Cannabis use on mortality rates are not clear-cut. 
Recent reviews found that studies on effects of acute Cannabis intoxication on driving fatalities have 
inconsistent results, with some studies reporting increased risk, some no effect, and some decreased 
risk in users [207-209]. Following meta-analysis, Asbridge et al. [207] concluded that acute Cannabis 
intoxication approximately doubled the risk of fatal collisions (OR for collisions = 1.92, OR for fatal 
collisions = 2.1, OR for culpability = 1.65). Another systematic review and meta-analysis failed to 
detect any significant effect of Cannabis use on fatal (OR 1.26, 0.88 – 1.81) or injury (OR 1.10, 0.88 – 
1.39) crashes when data were adjusted for publication bias and other confounding factors [208]. A 
significant increase in property damage remained following adjustment, however (OR 1.26, 1.10 – 
1.44) [203]. Li et al. [209] obtained a summary odds ratio of 2.66 for crash risk.  
Following these studies, the “Crash Risk” study was performed by the National Highway Traffic 
Safety Association (NHTSA). In this, the largest study on crash risk associated with drug use in the 
U.S. [177], 3,000 crash-involved drivers and 6,000 control drivers were analyzed for illicit drug and 
alcohol use. The unadjusted OR for Cannabis use and crash risk was 1.25 (P = 0.01), resembling the 
results of Elvik [208]. However, adjustment of the data for age, gender, and race/ethnicity further 
reduced the OR to 1.05 (P = 0.65), and additional adjustment for alcohol use reduced it further still, to 
a final OR of 1.00 (P = 0.98). In other words, this study, the largest of its kind, detected absolutely no 
impact of Cannabis use on crash risk [177] despite being sufficiently sensitive to show dose-
dependent increases in blood alcohol levels well below the legal limit. Drivers at the legal alcohol limit 
showed a four-fold increase in crash risk. Similarly, a longitudinal study of a birth cohort did not show 
increased risk of driving fatalities among Cannabis users when the data were adjusted for risky 
behaviors correlated with Cannabis use [210]. Thus, the evidence that Cannabis use increases the 
mortality rate from driving fatalities is weak, and the correlation may be driven by other factors, such 
as sex, age, and other confounding factors. This is supported by a series of studies that fail to find 
increased utilization of emergency services or hospitalizations by long-term Cannabis users [22-27, 
173-174]. Furthermore, increased risk during acute Cannabis intoxication does not necessarily 
translate into increased crashes or mortality at the population level, because users may alter behavior 
when using Cannabis. Possible compensatory changes include driving less often or shorter distances, 
avoiding roadways with higher speed limits, reducing alcohol consumption, or otherwise altering the 




Effect of changes in the legal status of Cannabis on driving fatalities:  
Legalization of marijuana provides a natural experiment to determine population-level changes 
in marijuana use on driving fatalities. Driving fatalities have been declining overall, for decades [211], 
Legalization of both medical and recreational marijuana use have been correlated with decreases in 
driving fatalities [13,211,212]. Anderson et al. [13] showed that driving fatalities decrease by 8 to 11% 
in the year following legalization of medical marijuana, a decrease driven primarily by reduced alcohol-
related driving deaths. Santaella-Tenorio analyzed data from states legalizing medical marijuana, and 
showed a immediate post-legalization decrease in traffic fatalities of 10.8% [211]. Santaella-Tenorio et 
al. [211] performed an extensive analysis of driving fatalities in states legalizing medical marijuana, 
using data from the 1985 – 2014 Fatality Analysis Reporting System. This study supported the 
analysis of Anderson et al. [13], showing immediate reductions in traffic fatalities among drivers aged 
15-24 yo, and additional yearly decreases among those aged 25-44, though no effects on older age 
groups were observed. Dispensaries were also associated with decreases in fatalities among those 
aged 25-44 [211]. As drivers aged 24-45 are disproportionately represented in driving fatalities (47%), 
this suggests that medical marijuana legalization has the greatest impact on the population at greatest 
risk for driving fatalities [211]. There was heterogeneity among states, with a couple of states showing 
increased fatalities while most showed decreases. The overall effect was a reduction of 10.8% in 
traffic fatalities in states legalizing medical marijuana, with California and New Mexico showing the 
largest immediate post-MMJ decreases, of 16% and 17.5% respectively, whereas Michigan saw an 
increase. As California is the largest state with legal access, the immediate, large decrease in fatalities 
would make an especially pronounced contribution to the effect of legalization on driving fatalities. 
Balko [212] analyzed data from the Colorado Department of Transportation, and showed that driving 
fatalities decreased following legalization of recreational use. Illicit Cannabis use may therefore 
decrease driving fatalities in other states where it remains illegal, an effect that was invisible until 
revealed by changes in legal status, though replicated data from states legalizing recreational 
Cannabis use are not yet available.  
The data presented by Anderson et al. [13] are used in the analysis because they are the only 
numerical values encountered during the search that can be entered into Formula 2 (Balko [212] did 
not give numerical data). Odds ratios for driving fatalities when acutely intoxicated cannot be used to 
estimate effects of Cannabis use on driving fatalities from the values for the proportion of the 
population using Cannabis each month, as it is not clear how many users consistently drive when 
acutely intoxicated. 
The proportion of drivers involved in fatal accidents who test positive for Cannabis use has 
increased in Colorado [213] and Washington State [214] following legalization. However, like overall 
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risk during acute intoxication, this does not mean that Cannabis use increases population level crash 
risk, as these studies did not include controls who were not involved in accidents. If the proportion of 
drivers testing positive for Cannabis use who were not involved in a crash increased by the same 
amount as those who were, then Cannabis does not alter crash risk. As these data were not 
presented it is not possible to claim that observed increases in Cannabis use have caused an 
increase in crashes following legalization. In fact, data from the Colorado Department of 
Transportation show that driving fatalities decreased in Colorado following legalization of recreational 
use [212] despite evidence for large increases in the numbers of drivers testing positive for Cannabis 
[214]. Thus, it appears that, while driving under the acute influence of Cannabis may increase the risk 
of crash, driving fatalities paradoxically decrease following legalization of medical and recreational 
Cannabis use, possibly due to changes in driving behavior or substitution of Cannabis for alcohol, 




Assumptions of causation are justified by the relative impacts of Cannabis and alcohol use on 
driving [206] and on coordination [172], and the decrease in alcohol use upon legalization or initiation 
of medical marijuana [10-11,13]. For the current analysis, the most relevant studies for estimates of 
effects on mortality rates are those documenting changes in fatalities following changes in the legal 
status of Cannabis. Anderson et al. [13] reported an immediate post-MMJ decrease in traffic fatalities 
of 8-11%, while Santaella-Tenorio et al. [211] reported a very similar immediate decrease of 10.8%.  
According to the CDC [210], there were 35,369 driving fatalities in the U.S. in 2013. Using the 
data presented by Anderson et al. [13], an estimated 1,300 to 1,800 fewer driving fatalities/year in 
states with legal medical marijuana, and 12,800 to 17,500 fewer driving fatalities total since legal 
access began (Table 4). Had medical marijuana been legalized nationwide in 1996, an estimated 
53,750 to 73,900 fewer driving fatalities would have occurred during this time. These numbers are 
likely underestimates of the impact of Cannabis use, as the rate of drunk driving fatalities has 
decreased during this period and illicit Cannabis users may well have already shown reduced risk 
prior to legalization. 
 
Effects of medical marijuana on other alcohol-related fatalities: 
 
Evidence for changes in alcohol use due to decriminalization or legalization of recreational 
marijuana are mixed [203]. A recent review supports both substitution and complementarity of 
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Cannabis and alcohol under different conditions, finding that more liberal Cannabis laws are 
associated with reduced alcohol consumption [215]. The overall impact of recreational Cannabis use 
on alcohol use is therefore unclear. There is strong evidence, however, that legalization or use of 
medical marijuana reduces use of alcohol and prescription drugs [10-13,194-199]. If medical 




While the relationship between recreational Cannabis use and alcohol use is not yet clear, 
available data suggest that medical marijuana is associated with a decrease in alcohol consumption 
[10,11,13,198-199]. To obtain an estimate of non-driving alcohol-related fatalities, reported numbers 
of drunk driving fatalities (10,076/year; [216]) were subtracted from total estimates of alcohol-related 
deaths (88,000/year; [193,202]) to give 77,924 alcohol related fatalities/year from remaining causes. 
Assuming a linear relationship between consumption and risk, the reported 5% decrease in alcohol 
consumption in states following legalization of MMJ [13] gives an estimated decrease in non-driving 
alcohol-related deaths of 1,800 deaths/year (Table 4). Had the observed 10.6% reduction in number 
of drinks consumed during a drinking episode [13] been used in the analysis instead, this estimate 
would increase to 3,900 non-driving alcohol-related deaths prevented each year. These numbers are 
used as lower and upper estimates of the impact of medical Cannabis use on the alcohol-related 
mortality rate (Table 4). If MMJ were legal nationwide, these numbers would increase to 3,900 to 
8,300 deaths prevented each year. 
 
Effects of medical marijuana on suicide: 
Anderson et al. [217] analyzed state level suicide data from the National Vital Statistics Systems 
Mortality Detail files from 1990 to 2007, and found that suicide rates decreased 9.2 to 10.8% in young 
men aged 20-29, and 9.4 to 13.7% in men aged 30-39, in states legalizing MMJ relative to states with 
no legal access. No change was observed in suicide rates among young women [217]. However, 
subsequent studies that adjusted for additional confounding factors failed to detect a change in suicide 
rates following legalization of MMJ [218,219]. The estimate used in the current analysis is therefore a 
net change of zero in annual suicides in response to legalization of medical marijuana. Note that none 
of the studies found an increase in suicide rates. 
 




Published data show clear evidence for reduced deaths from cancer, diabetes mellitus, 
traumatic brain injury, in Cannabis users, and reduced deaths from opioid overdose, alcohol 
consumption, and driving fatalities. The greatest impacts of Cannabis use on the death rate are from 
effects of Cannabis use on rates of diabetes mellitus and cancer. These decreases are primarily 
associated with “recreational” use rather than medical use. The number of deaths from cancer, DM, 
and TBI decreases by an estimated 989 to 2,511 deaths for each 1% of the population using 
Cannabis. In addition, legalization of MMJ prevents an estimated 5,400 to 7,900 deaths each year in 
states with legal access, from reduced opioid overdose deaths, driving fatalities, and alcohol use. 
Under the regulatory policies in place in 2015, the effects of Cannabis use on mortality rates from all 
causes of death is estimated to be the prevention of between 17,400 to 38,500 deaths prevented/year 
assuming that 12.2% of the population uses Cannabis. If MMJ was currently legal in all states, the 
total reduction in premature deaths would increase to 23,500 to 47,500 at a 12.2% user rate (Table 5, 
Figure 4).  
These numbers are likely underestimates for several reasons. Laboratory studies suggest that 
Cannabis use reduces the incidence or progression of neurodegenerative and neuroinflammatory 
diseases, epilepsy, and harm from exposure to neurotoxins [4-7,161-167,181-186]. Alzheimer’s 
disease is responsible for a reported 84,747 [35], and possibly the underlying cause of as many as 
503,000 premature deaths annually [190], while Parkinson’s disease is responsible for 25,196 
deaths/year [35]. However, odds ratios for the effects of Cannabis use on incidences of or mortality 
from these neurodegenerative diseases are not available. Cannabinoids have also proven effective in 
reducing or eliminating the seizures characteristic of treatment-resistant epilepsy [189]. Furthermore, 
anti-epileptic and anti-Parkinsonism drugs caused 1,717 fatal overdoses in 2010 [158]. DM deaths are 
also likely underreported causing underestimation of DM deaths prevented by Cannabis use 
[107,108].  
Medical marijuana patients substitute Cannabis for prescription and illicit drugs [10-12,194-
199]. Drugs involved in overdose deaths include opioids, benzodiazepines, antidepressants, 
antiepileptic and antiparkinsonism drugs, antipsychotic and neuroleptic drugs, acetaminophen, 
barbiturates, NSAIDS, and muscle relaxants [158]. Recently, Bradford and Bradford [12] showed that 
prescriptions for drugs used to treat pain, anxiety, nausea, psychosis, seizures, sleep disorders, 
depression, and spasticity decrease following legalization of medical marijuana [12], yet data are not 
available for effects of legalization of MMJ on overdose deaths from drugs used to treat these 
conditions, other than opioids. Illicit use of Cannabis most likely reduced mortality rates from driving 
fatalities and overdoses prior to legalization, as the effects of Cannabis use on these causes of death 
only became visible when legal access increased the pool of people using Cannabis. Finally, 
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homicides and assaults are down in Colorado following legalization of recreational marijuana [178], 
although this most likely arises from cessation of prohibition rather than from Cannabis use itself. The 
present work therefore almost certainly significantly underestimates the number of premature deaths 
prevented by Cannabis use in the U.S. If so, further decreases in the mortality rate are expected with 





Scenario Deaths prevented Deaths prevented 
 Lower estimate Upper estimate 
12.2% user rate, under 
current medical policies 
17,400 38,500 
12.2% user rate, with legal 
medical MJ nationwide 
23,500 47,500 
 
Table 5: Summary of the meta-analysis: Estimated lives saved per year by Cannabis use, from all 
causes. ‘Current medical policies’ includes states with legal access to medical marijuana in 2015, while ‘legal 
medical MJ nationwide’ gives estimates assuming legal MMJ in all states.   
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Figure 4: Estimated annual numbers of premature deaths prevented by Cannabis use in the United 
States. The solid lines show estimated premature deaths prevented by Cannabis use under current medical 
marijuana policies (as of 2015). At the Y intercept are the deaths prevented by medical marijuana, while the 
slope represents the additional deaths prevented by “recreational” use as a function of the percent of the 
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population using Cannabis. The dashed lines show the number of premature deaths that would be prevented by 
Cannabis use if medical marijuana were legal nationwide, with the Y intercept the deaths prevented by medical 
marijuana alone and the slope showing the additional effects of recreational use, as above.  
Summary of the risk of bias across studies: 
Prior reviews, by including only adverse effects of Cannabis use and ignoring beneficial 
effects, have grossly misrepresented the public health impact of Cannabis use in the U.S. This has 
fed misconceptions of the public health impact of Cannabis use that have influenced research 
priorities and government policies. 
 
Estimation of the numbers of deaths caused by Cannabis prohibition: 
 
If Cannabis reduces the mortality rate, a hypothesis strongly supported by the analysis above, 
and assuming that prohibition decreases the number of people using Cannabis, then prohibition must 
increase the mortality rate. Evidence that prohibition decreases the number of people using Cannabis 
is clearly seen in changes following legalization of medical marijuana, and in Colorado following 
legalization of recreational marijuana. The current analysis shows that the difference in deaths from 
opioid overdose, driving fatalities, and alcohol-related causes in states that have legalized medical 
marijuana (MMJ) and those that have not is an estimated 6,100 to 9,000 deaths/year. These deaths 
can be directly attributed to prohibition. Note that these deaths can be attributed to prohibition even if 
prohibition has no effect on the “recreational” user rate. We can add to this number the increased 
deaths from cancer, diabetes mellitus, and traumatic brain injury that occurred because prohibition 
caused people to abstain who would otherwise use Cannabis. Each 1% decrease in the proportion of 
the population using Cannabis results in an estimated 989 to 2,511 additional premature deaths each 
year. The amount by which the user rate is decreased by prohibition is not known. If, however, 
prohibition causes a 3% decrease in Cannabis use (from 15.2 to 12.2%), and deaths from lack of 
access to MMJ are included, prohibition is responsible for an estimated 9,100 to 16,500 deaths each 
year, in the range of the mortality rate from opioid overdose (16,235) or homicides (16,121). A 7% 
decrease in the user rate would cause more deaths than Parkinson’s disease (25,196) [31](Figure 5). 
These calculations are almost certainly underestimates of the effects of prohibition, for reasons 
described above. Furthermore, prohibition has also almost certainly prevented the development of life-
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Figure 5: Annual estimates of premature deaths due to prohibition. The decrease in the percent of 
the population using Cannabis represents the effectiveness of prohibitionist policies. The Y-intercept 
shows the lower and upper estimates of the deaths attributed to lack of access to medical marijuana 
under current policies (as of 2015). The slopes of the lines are the 989to 2,511 additional deaths that 
occur each year from cancer, DM, and TBI for each 1% decrease in the user rate. The X- axis is the 
decrease in the proportion of the population using Cannabis in response to prohibition. The dashed lines 
show the numbers of deaths in 2010 from (A): Parkinson’s disease, (B): homicides or opioid overdose, 




This initial attempt to estimate the overall public health impact of Cannabis use, including both 
beneficial and harmful impacts on health, using published data, clearly suggests that Cannabis use is 
associated with a substantial decrease in the premature death rate.  
Based on the results of this extensive review of the evidence, it is time to change the 
discussion, from determining how much harm is caused by Cannabis use, to determining how many 
deaths are prevented by Cannabis use. This does not, of course, mean that Cannabis has no harmful 
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effects, just that beneficial effects may outweigh harmful effects on physical health. The most 
important determinant of health status is continued survival, and the results of this investigation 
strongly support the hypothesis that Cannabis use is associated with improved survival.  
The results of this analysis differ significantly from other recent studies that attempt to 
determine the public health impact of Cannabis use [18-21]. The current work includes factors (DM, 
cancer, TBI, MMJ) for which Cannabis use is associated with decreased mortality, effects that were 
either not known at the time, [19] or were not included [20,21] in prior analyses. The current analysis is 
also at odds with a number of studies that fail to detect changes in health or emergency room visits 
with Cannabis use [22-27]. The most likely cause of this discrepancy is that these longitudinal studies 
did not follow subjects long enough, as the longitudinal studies to date follow younger cohorts for 15 – 
20 years, into their mid-thirties or early middle age [22-23].  Decreased mortality from obesity-related 
diseases and cancer in Cannabis users would most likely not become apparent until later in life. For 
example, the decrease in rates of diabetes mellitus observed by Rajavashiseth et al. [76] was only 
apparent in subjects aged 40 – 59, and death from obesity-related conditions such as diabetes 
mellitus may take many years after onset of the disease.  
The results of the current analysis strongly suggest that Cannabis prohibition is a significant 
failure of public health policy, causing more harm than benefit. In addition to increasing the mortality 
rate, prohibition contributes to the largest per capita prison population in the world, interferes with 
pursuit of promising medical research, results in the loss of billions in potential tax revenues, 
empowers violent drug cartels thus destabilizing governments of neighboring countries, and causes 
extensive economic and electoral disenfranchisement of the most vulnerable U.S. communities. 
Furthermore, evidence available at this time suggests that prevention of Cannabis use by football 
players, people who are pre-diabetic or diabetic, people who may develop or have cancer, people 
suffering from chronic pain, epilepsy, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, 
and people who have been exposed to violence decreases their quality of life and/or increases their 
risk of death. This would seem to be a violation of basic human rights, especially as Cannabis is 
objectively less toxic than the widely used over-the-counter analgesic acetaminophen and many 
prescription drugs [158]. At present, prohibition creates the appearance that the criminal justice 
system is using taxpayer money to protect the profits of the pharmaceutical and private prison 
industries, in the process contributing to the systemic racism and voter disenfranchisement plaguing 
this country [223,224]. It is time to demand that politicians and the criminal justice system justify, if 
they can, the continuing harm caused to society by Cannabis prohibition when recent polls show that 




Limitations of this study: 
 
This study focuses on effects on premature death rates and does not claim that Cannabis has 
no harmful effects on individual health or society. Causes of morbidity that do not directly increase the 
death rate, such as Cannabis use disorder, are outside the scope of the study. The study focuses on 
population-level effects, which are by effects on the average user, rather than the worst outcomes 
arising in individuals with the highest levels of use. Estimates of impact of legalization of medical 
marijuana are based on average decreases across states and do not consider differences in 
population or demographics of individual states. The estimates are based on existing data revealed 
during extensive database searches, and these searches may have missed important data. Estimates 
of effects of Cannabis on the mortality rate from causes including neurodegenerative diseases and 
neurotoxins, epilepsy, those cancer types responsible for 30% of cancer diagnoses and 39% of 
cancer deaths, overdose deaths from prescription drugs other than opioids, and violence associated 
with Cannabis prohibition were not encountered during the search and were not included. The study 
is thus likely to underestimate significantly the actual impact of Cannabis use on the premature death 
rate. The numbers provided are thus rough estimates based on existing data, and it is anticipated that 
more refined analyses of more complete data will provide more accurate values. This study does not 
consider the indirect health effects of decreased life-long income due to the impact of drug law 
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